Jacqueline Cloos, PhD, of Amsterdam UMC, Amsterdam, The Netherlands, outlines the findings of a study investigating splicing factor 3B subunit 1 (SF3B1) as a therapeutic target in patients with acute myeloid leukemia (AML) and an internal tandem duplication (ITD) in the FMS-like tyrosine kinase 3 (FLT3) gene. Dr Cloos describes how AML cells carrying spliceosome mutations are susceptible to SF3B1 modulation, meaning the development of a therapeutic modulator could be a viable treatment method. It was found that ITD/FLT3 AML cells treated with the SF3B1 modulator, E7107, were particularly susceptible to inhibition due to disruption of the cell cycle; however, overall survival was not seen to improve significantly. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.